Paracalcitolo Teva Italia (Paricalcitol)

Paricalcitol, the active ingredient in Paracalcitolo Teva Italia, is a vitamin D analog presented as a oral formulation for renal‑related calcium management use. It is employed primarily in patients with chronic kidney disease to control secondary hyperparathyroidism.

GNH USA supplies Paracalcitolo Teva Italia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

Paricalcitol is used within the management of disorders that affect calcium and phosphate metabolism, particularly in chronic kidney disease contexts. - Secondary hyperparathyroidism: Helps reduce elevated parathyroid hormone levels in patients on dialysis. - Hypercalcemia prevention: Assists in controlling calcium levels when vitamin D therapy is required. - Renal osteodystrophy: Contributes to better bone mineral balance in chronic kidney disease patients.

Paricalcitol may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Nausea: mild gastrointestinal discomfort. - Vomiting: occasional episodes of stomach upset. - Diarrhea: loose stools occurring intermittently. - Headache: mild to moderate head pain. - Fatigue: general feeling of tiredness. - Hypercalcemia: mild elevation of blood calcium levels.

Serious or Rare Side Effects: - Severe hypercalcemia: marked increase in serum calcium requiring medical intervention. - Hyperphosphatemia: significant rise in phosphate levels. - Allergic reaction: rash, itching, or swelling indicative of hypersensitivity. - Acute kidney injury: sudden decline in renal function. - Cardiac arrhythmia: irregular heart rhythm linked to electrolyte disturbances.

Paricalcitol should be used with careful clinical monitoring and adherence to prescribing information. - Monitor calcium and phosphate: regular blood tests are required to track mineral levels. - Adjust dose in renal impairment: dosing may need modification based on kidney function. - Avoid in uncontrolled hypercalcemia: the drug can exacerbate high calcium levels. - Caution in pregnancy: limited data; use only if potential benefit outweighs risk. - Review concomitant vitamin D therapy: assess total vitamin D exposure. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Paricalcitol can interact with several medicines that influence calcium, phosphate or vitamin D metabolism.

Major Interactions (Avoid): - Calcium supplements: may cause excessive calcium accumulation. - High‑dose vitamin D analogues: increase risk of hypercalcemia. - Thiazide diuretics: can raise serum calcium levels.

Moderate Interactions (Monitor Closely): - Phosphate binders: may alter absorption of paricalcitol. - Corticosteroids: can affect calcium balance and bone metabolism. - Antifungal azoles (e.g., ketoconazole): may interfere with vitamin D metabolism.